Silicon Valley giant NVIDIA is teaming up with pharma company AstraZeneca and the University of Florida on new artificial intelligence research projects aimed at boosting drug discovery and patient care.
This morning NVIDIA and AstraZeneca revealed a new drug-discovery model called MegaMoIBART, which is aimed at "reaction prediction, molecular optimization and de novo molecular generation."...
(Photo by Klaus Vedfelt/Getty Images)
Digital therapeutics company Pear Therapeutics is looking to integrate digital biomarkers, machine learning algorithms and sensor-based technologies into its platform thanks to new licensing deals and partnerships.
The Boston-based DTx company has inked collaboration deals with Empatica and etectRx, as well as licensing tech from KeyWise.
Specifically, Pear's collaboration with Empatica will...
(Photo by Sebastian Kaulitzki/Getty Images)
Those keeping an eye on the digital therapeutics industry over the last several years likely remember the name Dthera Sciences.
The startup and its CEO Ed Cox became one of the developing space's many standard bearers around 2018. During that timeframe it landed a Breakthrough Device designation from the FDA for its Alzheimer's symptoms treatment, with Cox chairing a handful of industry...
(Photo credit: Getty Images/Westend61)
Over the last year, digital has transformed the caregiver experience, but pharma has also been undergoing a metamorphosis in order to reach patients.
During the pandemic, life science companies were pushed to reconfigure their care in order to meet the needs of some of the most at-risk patients. MobiHealthNews sat down with the leader of pharma giant Otsuka's Global Clinical Development on...
(Photo by Audtakorn Sutarmjam / EyeEm/Getty Images)
Dr. Amy Abernethy, Principal Deputy Commissioner and Acting Chief Information Officer at the FDA, will be stepping down from her positions at the agency in mid-to-late April, according to a memo Acting FDA Commissioner Dr. Janet Woodcock sent out to agency staff this morning.
Abernethy came to the agency in early 2019 following a long line of executive and board positions at healthcare and health...
The history of pharma and provider partnerships spans back decades, and has traditionally focused on the development of new drugs. Digital is coming into the fold of health, forcing those partnerships to go through a metamorphosis to include new tech.
“Industry and academia have been working together for decades in a pharmaceutical sector, but historically the relationships did not extend beyond...
(Photo by MR.Cole_Photographer/Getty Images)
AI isn't ready for COVID-19 prime time. A systematic review of published this week in nature machine intelligence warns that new models using machine learning to review chest radiographs and chest computed tomographies for COVID-19 have major methodical deficiencies or underlying biases.
Among the 62 published or pre-print papers outlining these approaches, the authors wrote that not a single one...
IMA Clinical Research, a division of the IMA Group that provides clinical evaluation and research services, has partnered with AiCure to deploy the patient engagement company's Patient Connect tool to patients in a new effort to observe health management beyond the traditional study setting.
The 30-day program will have participants using the smartphone app to confirm adherent dosing behavior and...
Diabetes management company Welldoc is teaming up with Eli Lilly on a new licensing and collaboration agreement that promises to integrate the former’s software into the pharma company’s insulin products, which are still in the pipeline.
The partners plan on creating a new version of Welldoc’s BlueStar, an app-based diabetes management platform that will be able to integrate insulin dosing data...
It’s no secret that Click Therapeutics is on a roll with pharma partnerships. The mental health-focused digital therapeutic company made headlines this week when it announced a new clinical trial with Japanese pharma company Otsuka, based on a deal made in 2019.
But this isn't the only deal the New York-based company worked on with the life science industry. In September, the company signed a $...
